Long-term outcomes of GIST patients receiving adjuvant therapy

Knight Diagnostic Laboratories' Christopher Corless, MD and OHSU oncologists Drs. Charles Blanke and Michael Heinrich are among the co-authors in a study recently published in the J Clinical Oncology assessing the long-term outcomes GIST patients receiving adjuvant therapy: 

Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, Dematteo RP. J Clin Oncol. 2014 Mar 17.